Connect with us

Startup

Investors to Lose Hopes in India due to the Domination by Narrow Capitalists

India waved a green flag to unlock the capital in smaller airports two years ago. However, the plan is not very assuring. It is worrying for investors that privatization of all the six airports on the block went to one bidder.  The disturbance has hiked as the multimedia reports say that Gautam Adani, Gujarat-based billionaire, […]

Avatar

Published

on

India waved a green flag to unlock the capital in smaller airports two years ago. However, the plan is not very assuring. It is worrying for investors that privatization of all the six airports on the block went to one bidder. 

The disturbance has hiked as the multimedia reports say that Gautam Adani, Gujarat-based billionaire, early and fervent supporter of PM Modi, may also get the already privatized Mumbai-airport and the new one on its outskirts. 

If we have one tycoon owning several airports, natural monopolies, is not a good news, especially for airlines, businesses operating in the premises, and fliers. There is a broader trend going in the country for the concentration of economic power in the aviation infrastructure. Similarly, in other businesses where the key ingredient is the supplies of government like the telecom spectrum. 

In the Current Scenario, Foreign Investors Ardor in India is Unclear

Investors are worried that there may not be enough space in the market due to the dominance of narrow capitalists. They may not be willing to compete since, in most sectors, state policy determines the winner. The business class in India overextended apart from certain exceptions. It is confined in the rubble of assets built on the loans from state-run banks. These directed loans are from pliant money lenders, where a call can decide who gets the credits.

However, it is tough for India to carry on this way. In the post-COVID-19 world, government-owned banks of the country would require about 28 billion USD in external capital for at least two years. It would raise the loss provisions in the rancid loans to 70%, says the Moody’s Investors Service (1). They further added that gaining such capital would also help banks double their credit scores from the previous financial year by 4%.

The capital must come from an organization that can’t keep a lid on its borrowing costs. Hence, there is no question to recover the economy sharply and fueled with credit recovery. It could be why the policymakers are letting tycoons with the healthy financial muscle take what they can.  

The investors got a new ray of hopes when India unveiled a new bankruptcy law in 2016. The investors were expecting an equal chance to take productive assets from weak hands. However, this may not be where the country is heading. The government of India must ensure a competitive economy with state assets. Else, the corporate in India, may start looking like a board of Monopoly. 


Rucha Joshi is fueled by her passion for creative writing. She is eager to turn information into action. With her hunger for knowledge, she considers herself a forever student. She’s currently working as a content writer and is always interested in a challenge.

Source: https://timesnext.com/investors-to-lose-hopes-in-india-due-to-the-domination/

Startup

FDA approves remdesivir as the first treatment for COVID-19 despite WHO-sponsored study that shows remdesivir FAILED to prevent COVID-19 deaths and did NOT lower mortality rate in a multinational trial

Last week, we wrote about Gilead’s remdesivir (Veklury) after a new study of more than 11,000 people in 30 countries sponsored by the World Health Organization (WHO), found that remdesivir failed to prevent COVID-19 deaths in huge a trial. The study […]

The post FDA approves remdesivir as the first treatment for COVID-19 despite WHO-sponsored study that shows remdesivir FAILED to prevent COVID-19 deaths and did NOT lower mortality rate in a multinational trial appeared first on Tech News | Startups News.

Avatar

Published

on

Last week, we wrote about Gilead’s remdesivir (Veklury) after a new study of more than 11,000 people in 30 countries sponsored by the World Health Organization (WHO), found that remdesivir failed to prevent COVID-19 deaths in huge a trial. The study finds that the antiviral drug remdesivir has little or no effect on mortality for patients hospitalized with COVID-19 and failed to lower the mortality rate in a multinational trial.

Based on their findings, the team of scientists wrote:

“These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.”

Now in a new stunning development, the Food and Drug Administration (FDA) announced today it has “approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.”

FDA added that that remdesivir should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. FDA said that the approval does not include the entire population that had been authorized to use Veklury under an Emergency Use Authorization (EUA) originally issued on May 1, 2020.

“In order to ensure continued access to the pediatric population previously covered under the EUA, the FDA revised the EUA for Veklury to authorize the drug’s use for treatment of suspected or laboratory confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. Clinical trials assessing the safety and efficacy of Veklury in this pediatric patient population are ongoing,” FDA said in a public release.

“The FDA is committed to expediting the development and availability of COVID-19 treatments during this unprecedented public health emergency,” said FDA Commissioner Stephen M. Hahn, M.D. “Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed and represents an important scientific milestone in the COVID-19 pandemic. As part of the FDA’s Coronavirus Treatment Acceleration Program, the agency will to continue to help move new medical products to patients as soon as possible, while at the same time determining whether they are effective and if their benefits outweigh their risks.”

The agency also went on social media to promote the drug. In a Twitter post, FDA said:

“Today, we gave the first FDA approval for a #COVID19 treatment. The drug was approved for adults and children ages 12 and older for the treatment of #COVID19 requiring hospitalization. https://fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19”

On April 16, Gilead reported that early trial results from Remdesivir testing showed the drug to be effective in treating coronavirus patients in Chicago hospital. Then on April 23, an independent report from Financial Times, citing documents accidentally published by the World Organization, found that Remdesivir failed in a clinical trial. The report showed that Gilead Sciences’ remdesivir flopped in a Chinese trial aimed at treating coronavirus patients. The study found that Remdesivir did not improve patients’ condition or reduce the coronavirus pathogen in their bloodstream. In June, Gilead said it would make remdesivir at a cost $3,120 per U.S. patient.

Below is the Abstract of the WHO-sponsored study.

BACKGROUND WHO expert groups recommended mortality trials in hospitalized COVID-19 of four re-purposed antiviral drugs. METHODS Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a (mainly subcutaneous; initially with Lopinavir, later not). COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control (up to 5 options: 4 active and local standard-of-care). The intent-to-treat primary analyses are of in-hospital mortality in the 4 pairwise comparisons of each study drug vs its controls (concurrently allocated the same management without that drug, despite availability). Kaplan-Meier 28-day risks are unstratified; log-rank death rate ratios (RRs) are stratified for age and ventilation at entry. RESULTS In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug. Compliance was 94-96% midway through treatment, with 2-6% crossover. 1253 deaths were reported (at median day 8, IQR 4-14). Kaplan-Meier 28-day mortality was 12% (39% if already ventilated at randomization, 10% otherwise). Death rate ratios (with 95% CIs and numbers dead/randomized, each drug vs its control) were: Remdesivir RR=0.95 (0.81-1.11, p=0.50; 301/2743 active vs 303/2708 control), Hydroxychloroquine RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), Lopinavir RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372) and Interferon RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050). No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration.

CONCLUSIONS These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials. (Funding: WHO. Registration: ISRCTN83971151, NCT04315948)


Source: https://techstartups.com/2020/10/22/fda-approves-remdesivir-first-treatment-covid-19-despite-sponsored-study-showed-remdesivir-failed-prevent-covid-19-deaths-not-lower-mortality-rate-mu/

Continue Reading

Startup

Former Chief Science Officer for Pfizer: Coronavirus “pandemic is over” and “there is no science to suggest a second wave should happen.” It’s faked on false-positive COVID-19 tests

In a reversal about what the public health officials and scientists have been telling us for months, Dr. Mike Yeadon, the former Chief Science Officer for the pharmaceutical giant Pfizer says “there is no science to suggest a second wave should happen.” […]

The post Former Chief Science Officer for Pfizer: Coronavirus “pandemic is over” and “there is no science to suggest a second wave should happen.” It’s faked on false-positive COVID-19 tests appeared first on Tech News | Startups News.

Avatar

Published

on

In a reversal about what the public health officials and scientists have been telling us for months, Dr. Mike Yeadon, the former Chief Science Officer for the pharmaceutical giant Pfizer says “there is no science to suggest a second wave should happen.” Dr. Yeadon said that false-positive results from inherently unreliable COVID tests are being used to manufacture a “second wave” based on “new cases.”

With a degree in biochemistry and toxicology and a research-based Ph.D. in respiratory pharmacology, Dr. Mike Yeadonhas spent over 30 years leading new medicines research in some of the world’s largest pharmaceutical companies. He worked for Pfizer for 16 years before in 2011 as Vice President & Chief Scientist for Allergy & Respiratory. Since leaving Pfizer, Dr. Yeadon has founded his own biotech company, Ziarco, which was sold to the world’s biggest drug company, Novartis, in 2017.

In an interview with Julia Hartley-Brewer, Dr. Yeadon said the Government is “using a test with an undeclared false positive rate.” He said that he wants those who have tested positive for coronavirus to be tested again to eliminate the possibility of the test being a false positive.

Even if all positives were to be correct, Dr. Yeadon explained that given the “shape” of all important indicators in a worldwide pandemic, such as hospitalizations, ICU utilization, and deaths, “the pandemic is fundamentally over.”

“Were it not for the test data that you get from the TV all the time, you would rightly conclude that the pandemic was over, as nothing much has happened. Of course people go to the hospital, moving into the autumn flu season…but there is no science to suggest a second wave should happen,”  Yeadon said in the interview.

You can watch the video of his interview below.

Back in September, Dr. Yeadon also co-authored a paper with two of his colleagues. In the paper, which is titled: “How Likely is a Second wave?” they explained:

“It has widely been observed that in all heavily infected countries in Europe and several of the US states likewise, that the shape of the daily deaths vs. time curves is similar to ours in the UK. Many of these curves are not just similar, but almost super imposable.”

Dr. Yeadon and the two scientists also looked at the national weekly mortality data from the UK to see the effect of the COVID-19 pandemic. They used the data of the past four years for comparison purposes and to calculate upper and lower control limits (based on two standard deviations).

Below is how they described their findings:

This shows that in the pandemic peak (April 17th to 30th) more than twice the number of seasonal average deaths occurred, with the number of deaths above the upper control limit from March 27th through to June 12th, totalling 44,895 excess deaths. Since June 26th the number of weekly deaths has now fallen so it is not only below the weekly average but has regularly dropped below the lower control limit, showing that we are now at the lowest number of weekly deaths recorded in many years.

Based on their study, they found that “over the last three months since lockdown measures started easing on the May 10th there has been no increase in weekly deaths. On the contrary, these have continued to fall.

Dr. Yeadon further pointed out that the “novel” COVID-19 contagion is novel only in the sense that it is a new type of coronavirus. But, he said, there are presently four strains which circulate freely throughout the population, most often linked to the common cold.

Yeadon et al added:

“There are at least four well characterised family members (229E, NL63, OC43 and HKU1) which are endemic and cause some of the common colds we experience, especially in winter. They all have striking sequence similarity to the new coronavirus.”

Toward the end of the paper, Dr. Yeadon and the two other scientists also addressed the sudden surge in coronavirus cases and what is happening in terms of second wave concerns in France and Spain. They “contend that the many claims in the media for outbreaks, spikes and second waves are all artefacts of amplified rates of testing.”

“It should be noted that illness, hospitalisations and deaths have not reversed in any clear and sustained manner. Specifically, careful examination of the weekly all-causes mortality data in France is completely clear. Six weeks into an apparent surge of cases, the number of deaths remain completely flat and normal, in all age bands (as of mid-August when this document was written).”

The authors concluded with recent charts of daily cases from the two countries to further support their claim that the second wave is over.

R


Source: https://techstartups.com/2020/10/22/former-chief-science-officer-pfizer-coronavirus-pandemic-no-science-suggest-second-wave-happen-faked-false-positive-covid-19-tests/

Continue Reading

Startup

ZenSports, the mobile peer-to-peer sports betting app, launches support for native cryptocurrency for funding, betting, and trading in ICX

The first time we wrote about ZenSports was back in February of this year. Since then, the crypto-based gaming startup has been getting a lot of attention from tech investors and partnerships. Just last month, closed an additional $1.46 million seed […]

The post ZenSports, the mobile peer-to-peer sports betting app, launches support for native cryptocurrency for funding, betting, and trading in ICX appeared first on Tech News | Startups News.

Avatar

Published

on

The first time we wrote about ZenSports was back in February of this year. Since then, the crypto-based gaming startup has been getting a lot of attention from tech investors and partnerships. Just last month, closed an additional $1.46 million seed funding for its mobile peer-to-peer sports betting marketplace.

Today, ZenSports just announced the launch of funding, betting, and trading in ICX. The ICX is the native coin built on ICON’s blockchain protocol, and which can be used for real-time payments and also as a protocol for connecting the blockchain world. With the launch, ZenSports now includes the native cryptocurrency from ICON’s blockchain protocol, ICX, to its platform for funding, betting, and trading.

Founded in 2016 by Etan Mizrahi-Shalom and Mark Thomas, the San Francisco, California-based ZenSports is a mobile peer-to-peer sports betting marketplace where anyone can create and accept sports bets with anyone else in the world, without the need for a centralized bookmaker. ZenSports is the only native mobile app that offers peer-to-peer sports betting on the App and Play Stores.

Up until now, ZenSports has accepted USD (both fiat and cryptocurrency versions of USD), Bitcoin, and its native SPORTS token (which is also built on ICON’s protocol). With the addition of ICX onto its platform, ZenSports customers can now quickly deposit ICX into their accounts, wager on sports using ICX, and buy/sell/trade ICX within the ZenSports trading exchange. Customers can also withdraw ICX directly from their ZenSports accounts.

ZenSports originally partnered with ICON back in June 2018, when ICON invested in ZenSports’ Pre-Seed round. ZenSports then built and launched its SPORT security token on ICON in December 2018, and built and launched its SPORTS utility token on ICON in July 2019.

According to ZenSports co-founder and CEO Mark Thomas, “ICON has been an amazing partner of ZenSports’ for the past two years. Their blockchain technology is second to none, settlement times for transactions are near-instant, and the fees are extremely low. The community is awesome, and the management team is extremely responsive and helpful whenever we have questions. We’re excited to give back to the ICON community through our launch of ICX funding, betting, and trading within ZenSports.”


Source: https://techstartups.com/2020/10/22/zensports-mobile-peer-peer-sports-betting-app-launches-support-native-cryptocurrency-funding-betting-trading-icx/

Continue Reading
Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Saas2 hours ago

Press Releases3 hours ago

Hurricane Epsilon Marks 10th Hurricane of the 2020 Hurricane Season

Press Releases3 hours ago

TransAlta Renewables Executes 15-year Contract Extension in Western Australia with BHP Nickel West

Press Releases3 hours ago

Hurricane Epsilon Marks 10th Hurricane of the 2020 Hurricane Season

Press Releases3 hours ago

ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Loop Industries, Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm – LOOP

Press Releases3 hours ago

Taseko To Release Third Quarter 2020 Results

Press Releases3 hours ago

Revolt Announces Compelling New Social Justice Documentary ‘From Pain to Power: A Revolt Special’ to Premiere on Monday, October 26th

Venture Capital3 hours ago

8common (ASX:8CO) raises $2.25M in extra capital

Venture Capital3 hours ago

Australian government to review domestic payments system regulation

Press Releases4 hours ago

Agape Treatment Center Launches Neuro Program to Improve Success of Addiction Treatment

Saas4 hours ago

25% of You in SF Plan to Go Back to The Office Soon, Apparently

Press Releases4 hours ago

Gulfcoastguys.com explains why vacation rentals are better than hotels – our website will show you the best rentals in Sarasota and Bradenton Florida.

Venture Capital4 hours ago

Bitcoin goes mainstream as institutional ‘wall of money’ begins buying

Press Releases4 hours ago

Publish your press release in Baidu in Chinese

Venture Capital4 hours ago

Wisr Warehouse funding facility upsized to $250 million

Venture Capital4 hours ago

Australian Fintech Parpera secures $800,000 through Equitise campaign

Startup4 hours ago

FDA approves remdesivir as the first treatment for COVID-19 despite WHO-sponsored study that shows remdesivir FAILED to prevent COVID-19 deaths and did NOT lower mortality rate in a multinational trial

Press Releases5 hours ago

Local Debris Drop-Off Service Locations Now Available at Priority Waste

Press Releases6 hours ago

Helix Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option to Purchase Additional Shares

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Saas6 hours ago

Press Releases6 hours ago

Adams Resources & Energy, Inc. Completes Acquisition Of VEX Pipeline And Related Pipeline Terminal Facilities

Press Releases6 hours ago

Gerber Technology Redefines Mass Production with Launch of Revolutionary, Next-Generation Cutting Room

Trending